Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer (Q33331946)

25 July 2017

title

Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer (English)

1 reference

25 July 2017

1 reference

Udom DI

1

1 reference

25 July 2017

Vigushin DM

2

1 reference

25 July 2017

Linardou H

3

1 reference

25 July 2017

Graham H

4

1 reference

25 July 2017

Palmieri C

5

1 reference

25 July 2017

Coombes RC

6

1 reference

25 July 2017

publication date

1 January 2000

1 reference

European Journal of Cancer

25 July 2017

published in

1 reference

25 July 2017

volume

36

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

177-182

1 reference

Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900219-1

7 January 2021

10.1016/S0959-8049(99)00219-1

Identifiers

DOI

1 reference

25 July 2017

1 reference